Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Pulmonary thromboembolism in lung surgery: use of unfractionated heparin.

Yoshida J, Inoue M, Furugaki K, Oyama M, Oozono K.

Asian Cardiovasc Thorac Ann. 2014 Jan;22(1):46-8. doi: 10.1177/0218492313475672. Epub 2013 Oct 22.

PMID:
24585643
2.

Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.

Ugaki H, Enomoto T, Fujiwara K, Kimura T, Kawasaki T.

Blood Coagul Fibrinolysis. 2008 Sep;19(6):585-9. doi: 10.1097/MBC.0b013e32830708ad.

PMID:
18685443
3.
4.

Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.

de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, Hart HC, Sixma JJ, Nieuwenhuis HK.

Ann Intern Med. 1995 Jul 1;123(1):1-9.

PMID:
7539233
5.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
6.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.

N Engl J Med. 2001 Mar 1;344(9):626-31.

7.

Subcutaneous heparin for prophylaxis of venous thromboembolism in deep brain stimulation surgery: evidence from a decision analysis.

Bauman JA, Church E, Halpern CH, Danish SF, Zaghloul KA, Jaggi JL, Stein SC, Baltuch GH.

Neurosurgery. 2009 Aug;65(2):276-80; discussion 280. doi: 10.1227/01.NEU.0000348297.92052.E0.

PMID:
19625905
8.

Incidence of pulmonary thromboembolism in gastric cancer surgery using routine thromboprophylaxis.

Saka M, Morita S, Fukagawa T, Nijjar R, Katai H.

Gastric Cancer. 2010 Jun;13(2):117-22. doi: 10.1007/s10120-010-0551-6. Epub 2010 Jul 3.

PMID:
20602199
9.

Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

B├╝ller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators.

N Engl J Med. 2003 Oct 30;349(18):1695-702. Erratum in: N Engl J Med. 2004 Jan 22;350(4):423.

10.

Aggressive venous thromboembolism prophylaxis reduces VTE events in vascular surgery patients.

Durinka JB, Hecht TE, Layne AJ, Jackson BM, Woo EY, Fairman RM, Rohrbach JI, Wang GJ.

Vascular. 2016 Jun;24(3):233-40. doi: 10.1177/1708538115594094. Epub 2015 Jun 29.

PMID:
26123057
12.

Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice.

Zidane M, Schram MT, Planken EW, Molendijk WH, Rosendaal FR, van der Meer FJ, Huisman MV.

Arch Intern Med. 2000 Aug 14-28;160(15):2369-73.

PMID:
10927736
13.

Three-times-daily subcutaneous unfractionated heparin and neuraxial anesthesia: a retrospective review of 928 cases.

Davis JJ, Bankhead BR, Eckman EJ, Wallace A, Strunk J.

Reg Anesth Pain Med. 2012 Nov-Dec;37(6):623-6. doi: 10.1097/AAP.0b013e31826a8d10.

PMID:
22996202
14.

Systemic effects of subcutaneous heparin use in otolaryngology patients.

Blank SJ, Grindler DJ, Zerega J, Blinder M, Nussenbaum B.

Otolaryngol Head Neck Surg. 2014 Dec;151(6):967-71. doi: 10.1177/0194599814552055. Epub 2014 Sep 25.

PMID:
25257903
15.

Dalteparin versus unfractionated heparin in critically ill patients.

PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE.

N Engl J Med. 2011 Apr 7;364(14):1305-14. doi: 10.1056/NEJMoa1014475. Epub 2011 Mar 22.

16.

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.

Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF.

Arch Intern Med. 2000 Jan 24;160(2):229-36.

PMID:
10647762
17.

Changes of D-dimer after total hip arthroplasty in patients with and without intraoperative heparin.

Maezawa K, Nozawa M, Aritomi K, Kubota M, Shitoto K, Kurosawa H.

Arch Orthop Trauma Surg. 2008 Jan;128(1):37-40. Epub 2007 May 24.

PMID:
17522875
18.

Subcutaneous heparin does not increase postoperative complications in neurosurgical patients: An institutional experience.

Hacker RI, Ritter G, Nelson C, Knobel D, Gupta R, Hopkins K, Marini CP, Barrera R.

J Crit Care. 2012 Jun;27(3):250-4. doi: 10.1016/j.jcrc.2011.09.005. Epub 2012 Jan 4.

PMID:
22226424
19.

Complications of subcutaneous low-dose heparin therapy in neurosurgical patients.

Wen DY, Hall WA.

Surg Neurol. 1998 Dec;50(6):521-5.

PMID:
9870811
20.

Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).

Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J; ECHOS Trial Group.

Int Angiol. 2006 Dec;25(4):335-42.

PMID:
17164738

Supplemental Content

Support Center